JP2022553421A5 - - Google Patents

Info

Publication number
JP2022553421A5
JP2022553421A5 JP2022524928A JP2022524928A JP2022553421A5 JP 2022553421 A5 JP2022553421 A5 JP 2022553421A5 JP 2022524928 A JP2022524928 A JP 2022524928A JP 2022524928 A JP2022524928 A JP 2022524928A JP 2022553421 A5 JP2022553421 A5 JP 2022553421A5
Authority
JP
Japan
Prior art keywords
formula
pharmaceutical composition
chemotherapeutic agents
compound
immune checkpoint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022524928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022553421A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/060104 external-priority patent/WO2021084441A2/en
Publication of JP2022553421A publication Critical patent/JP2022553421A/ja
Publication of JP2022553421A5 publication Critical patent/JP2022553421A5/ja
Pending legal-status Critical Current

Links

JP2022524928A 2019-10-28 2020-10-28 がんの処置のための方法および組成物 Pending JP2022553421A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926963P 2019-10-28 2019-10-28
US62/926,963 2019-10-28
PCT/IB2020/060104 WO2021084441A2 (en) 2019-10-28 2020-10-28 Methods and compositions for treatment of cancer

Publications (2)

Publication Number Publication Date
JP2022553421A JP2022553421A (ja) 2022-12-22
JP2022553421A5 true JP2022553421A5 (enExample) 2023-11-07

Family

ID=75714907

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524928A Pending JP2022553421A (ja) 2019-10-28 2020-10-28 がんの処置のための方法および組成物

Country Status (6)

Country Link
US (1) US20220370397A1 (enExample)
EP (1) EP4051260A4 (enExample)
JP (1) JP2022553421A (enExample)
KR (1) KR20220114532A (enExample)
CN (1) CN114650815A (enExample)
WO (1) WO2021084441A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220339135A1 (en) * 2019-01-07 2022-10-27 Enzychem Lifesciences Corporation Compositions and methods for modulating an inflammatory response
JP2022526210A (ja) * 2019-01-16 2022-05-24 エンジーケム ライフサイエンシーズ コーポレーション がんの処置のための方法および組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100283010B1 (ko) * 1997-11-20 2001-04-02 전길자 녹용 추출물을 함유하는 조혈모세포 및 혈소판 전구세포 증식촉진용 조성물
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
CA2562897C (en) * 2004-04-24 2011-03-15 Sang-Hee Kim Immunomodulating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives
CA2921841C (en) * 2013-08-19 2018-06-19 Korea Research Institute Of Bioscience And Biotechnology Composition containing monoacetyldiglyceride compound as active ingredient for inhibiting blood cancer or metastasis
AU2015258840B2 (en) * 2014-05-15 2018-03-15 Enzychem Lifesciences Corporation Methods for treating leukopenia and thrombocytopenia
KR20170122810A (ko) * 2015-03-04 2017-11-06 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 에리불린의 조합
MX388579B (es) * 2016-01-08 2025-03-20 Euclises Pharmaceuticals Inc Combinacion de un compuesto de cromeno y un segundo agente activo.
US10688104B2 (en) * 2016-05-20 2020-06-23 Eli Lilly And Company Combination therapy with Notch and PD-1 or PD-L1 inhibitors
JP7250674B2 (ja) * 2016-08-08 2023-04-03 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がんの治療及び診断方法
KR20190063536A (ko) * 2017-11-30 2019-06-10 주식회사 엔지켐생명과학 1-팔미토일-2-리놀레오일-3-아세틸글리세롤을 포함하는 급성 방사선 증후군의 예방 또는 치료용 조성물
JP2022526210A (ja) * 2019-01-16 2022-05-24 エンジーケム ライフサイエンシーズ コーポレーション がんの処置のための方法および組成物

Similar Documents

Publication Publication Date Title
JP2006501176A5 (enExample)
JP2018058847A5 (enExample)
JP2021063088A5 (enExample)
JP2019519467A5 (enExample)
JP2008543854A5 (enExample)
JP2009536221A5 (enExample)
JP2007523185A5 (enExample)
JP2019510746A5 (enExample)
RU2009112686A (ru) Окисленные липиды и их применение для лечения воспалительных заболеваний и нарушений
JP2006505543A5 (enExample)
JP2005533835A5 (enExample)
JP2020506951A5 (enExample)
JP2015508103A5 (enExample)
AU2017258304B2 (en) 1,5-disubstituted 1,2,3-triazoles are inhibitors of Rac/Cdc42 GTPases
JP2011506274A5 (enExample)
JP5149177B2 (ja) 増殖性疾患の治療のための、チューブリンポリマー化の1,2,3−トリアゾール系抑制剤
EP4051283A1 (en) P53 modulators and uses thereof
JP2024513505A5 (enExample)
JP2018525425A5 (enExample)
JP2007502295A5 (enExample)
JP2025503521A5 (enExample)
JP2024502178A5 (enExample)
EP0095663B1 (en) Organic selenium compounds having an anti-neoplastic activity
JP2023510797A5 (enExample)
JP2021536472A5 (enExample)